SGMT
SGMT
US7867001049
Sagimet Biosciences Inc. - Seri
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 75/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±148.8% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves approx. 3.5x as much as the broader market.

Beta (Market Relation)
3.49x
Above average
Volatility (3Y p.a.)
148.8% p.a.
Fallback
Max Drawdown (3Y)
-89.7%
Fallback
Sharpe Ratio
0.01
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +22%
3 Years 148.8% -89.7% 0.01 +4%
5 Years — — — —
10 Years — — — —

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
High market risk: Beta of 3.49 indicates above-average volatility compared to the broader market.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
10 ISS Score: 10 / 10
Audit Risk
7 ISS Score: 7 / 10
Board Risk
8 ISS Score: 8 / 10
Short Ratio
9.88
ende